Stockscreener 앱 받기
101.82
2.23%
2.22
시간 외 거래:
101.47
-0.35
-0.34%
전일 마감가:
$99.60
열려 있는:
$100
하루 거래량:
6.83M
Relative Volume:
0.74
시가총액:
$176.19B
수익:
$46.59B
순이익/손실:
$5.41B
주가수익비율:
32.91
EPS:
3.0938
순현금흐름:
$7.38B
1주 성능:
+1.72%
1개월 성능:
-0.13%
6개월 성능:
+1.52%
1년 성능:
-23.20%
1일 변동 폭
$99.78
$102.06
1주일 범위
$97.20
$102.06
52주 변동 폭
$81.97
$134.50
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs MDT, SYK, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
101.82 | 176.19B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.93 | 117.59B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
282.60 | 108.40B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.84 | 63.53B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.39 | 49.80B | 6.30B | 1.07B | 1.09B | 1.8406 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-07 | 개시 | Barclays | Overweight |
| 2026-10-02 | 업그레이드 | Rothschild & Co Redburn | Neutral → Buy |
| 2026-08-13 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2026-07-01 | 개시 | Robert W. Baird | Outperform |
| 2026-04-22 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026 - GlobeNewswire Inc.
History Says Abbott Stock Could More Than Double by 2036. Here’s Why I Just Added It to My Portfolio. - The Motley Fool
A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens - The Motley Fool
Cancer Stocks to Consider as Oncology Innovation Accelerates - Zacks Investment Research
Is it the Right Time to Hold TNDM Stock in Your Portfolio? - Zacks Investment Research
China Adult Feeding Tubes and Formula Market Outlook to 2033Revenue, Volume, Pricing, and Company Share | Forecast Data Reveals Market Entry and Expansion Opportunities - GlobeNewswire Inc.
Is it the Right Time to Add Phibro Stock to Your Portfolio? - Zacks Investment Research
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research
Abbott Laboratories Contamination Lawsuit Ends in $385 Million Settlement — But Nobody's Admitting Anything - https://www.lawnews.co.uk/
Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note - Zacks Investment Research
What Will the Libre Duo Launch Mean for Abbott Laboratories (NYSE:ABT)? - Kalkine Media
Abbott Laboratories stock: FDA approves new CardioMEMS capabilities - AD HOC NEWS
Did Heart Failure Device Updates Just Shift Abbott Stock’s Investment Narrative? - Simply Wall Street
Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight - GlobeNewswire Inc.
Better Dividend Play for Retirees: MDT or ABT? One Delivers Significantly More Yield - 24/7 Wall St.
Abbott Laboratories stock trades 26.5 percent below its yearly high - AD HOC NEWS
Can J&J's MedTech Business Rebound in Q3 After Q2 Slowdown? - Zacks Investment Research
Redburn upgrades Abbott Laboratories stock to Buy - AD HOC NEWS
Global Microfluidics Market by Product Type, Application, End User, and Region, 2026-2036 | $48.04 Billion Opportunity Driven by Point-of-Care Diagnostics and Automation - GlobeNewswire Inc.
Grace Groner bought three $60 shares of Abbott Laboratories in 1935 and worked there 43 years; she left more than $7 million to benefit Lake Forest College students when she died at 100 - Parade Magazine
AG Fitch announces $384M false claims settlement with Abbott Laboratories - Picayune Item
Abbott Laboratories stock outperforms competitors on strong trading day - MarketWatch
Abbott Laboratories Stock (ABT) Moved Up by 3.08% on Oct 5: Facts Behind the Movement - TradingKey
Europe Point of Care Diagnostics Market Size and Forecast, 20212031 | Market to Reach US$21.4 Billion by 2031 as Rapid Testing and Molecular Innovation Drive 13.4% CAGR - GlobeNewswire Inc.
The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies - Yahoo Finance
Abbott Laboratories (ABT) Launches SimpleScreen CRC As Fair Value Debate Heats Up - Simply Wall Street
How to Create a Million-Dollar Stock Portfolio - Zacks Investment Research
At $98.83 each, Abbott (ABT) director John G. Stratton acquires 397 share-linked units. - Stock Titan
DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care - Zacks Investment Research
Here Are Friday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, Airbnb, Cerebras Systems, Coinbase Global, Edison International, Northrop Grumman, Pershing Square, Robinhood Markets, and More - Yahoo Finance
Here Are Friday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, Airbnb, Cerebras Systems, Coinbase Global, Edison International, Northrop Grumman, Pershing Square, Robinhood Markets, and More - 24/7 Wall St.
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike - Zacks Investment Research
Rothschild & Co Redburn Upgrades Abbott Laboratories to Buy From Neutral, Adjusts PT to $127 From $119 - Yahoo Finance
Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Abbott Laboratories’ Quarterly Earnings Preview: What You Need to Know - Barchart.com
Abbott (ABT) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Zacks Investment Research
Abbott Laboratories stock trades at EUR 88.71 versus EUR 88.77, minus 0.07 percent - ad-hoc-news.de
Form 4 Abbott Laboratories For: 29 September By Investing.com - Investing.com UK
Abbott lawsuit alleges spinal cord stimulators can fail, worsen nerve damage - Top Class Actions
Global Therapeutic Drug Monitoring Consumables Market Forecast, 2026-2032AI-Enabled Automation and Integrated Lab Workflows Drive 8.22% CAGR, Lifting the Market to USD 586.85 Million by 2032 - GlobeNewswire Inc.
3 Dividend Stocks To Watch As High Rates Test Defensive Shares - simplywall.st
At $103.99 a share, an Abbott Laboratories (ABT) director delivered or withheld shares for exercise costs or taxes. - Stock Titan
How Lingo Partnership Will Impact Abbott Stock (ABT) - simplywall.st
Abbott Laboratories (ABT) is Facing Segment Competition and Sluggish Nutrition Recovery - Yahoo Finance
Mexico Cardiac Rhythm Management Devices Market Outlook to 2036 Provides Revenue, Volume, Pricing and Competitive Insig - GlobeNewswire Inc.
Abbott Laboratories: A Strong Business At A Fair Price (NYSE:ABT) - Seeking Alpha
Sinocare Asks Court To Rule Device Won't Infringe Abbott IP - Law360
Here's Why You Should Hold Stryker Stock in Your Portfolio for Now - Zacks Investment Research
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
애보트 래버러토리스 주식 (ABT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| John A. McCoy, Jr. | Officer |
Sep 02 '26 |
Proposed Sale |
109.52 |
27 |
2,957 |
0 |
| Robert B. Ford | Officer |
Aug 25 '26 |
Proposed Sale |
115.85 |
398,832 |
46,204,386 |
0 |
| Ford Robert B | CHAIRMAN AND CEO |
Aug 25 '26 |
Sale |
115.85 |
398,832 |
46,204,798 |
306,461 |
| Ford Robert B | CHAIRMAN AND CEO |
Aug 25 '26 |
Option Exercise |
54.02 |
398,832 |
21,545,946 |
705,293 |
| Morrone Louis H. | EXECUTIVE VICE PRESIDENT |
Aug 11 '26 |
Sale |
109.83 |
5,850 |
642,506 |
70,724 |
| Louis H. Morrone | Officer |
Aug 11 '26 |
Proposed Sale |
109.83 |
5,850 |
642,506 |
0 |
| Robert J. Alpern | Retired Director |
May 15 '26 |
Proposed Sale |
85.25 |
7,587 |
646,791 |
0 |
| Stratton John G | Director |
May 07 '26 |
Buy |
86.82 |
2,000 |
173,640 |
23,319 |
| STARKS DANIEL J | Director |
Apr 27 '26 |
Buy |
92.65 |
10,000 |
926,537 |
6,751,103 |
| Robert J. Alpern | Retired Director |
Apr 27 '26 |
Proposed Sale |
92.55 |
29,211 |
2,703,457 |
0 |
3.90%
자본화:
|
볼륨(24시간):